Most Oncology Approvals Using Surrogate Endpoints Lack Postmarket Confirmation, Study Says

Most of the new oncology indications approved under Real Time Oncology Review (RTOR) relied on surrogate endpoints that were never confirmed as clinically effective in postmarketing trials, according to a research letter published in JAMA Network Open.
Source: Drug Industry Daily